

**Novacyt S.A.**

**("Novacyt" or the "Company")**

## **Results of AGM**

**Paris, France and Camberley, UK – 20 July 2022** – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that all resolutions proposed at the ordinary general meeting part of the Company's Annual General Meeting (AGM), held today, were duly passed.

As part of the AGM, the Company also met today to hold an extraordinary general meeting. The meeting was not deemed quorate due to the minimum number of voting rights under French company law not being present or represented at the meeting. Consequently, the meeting did not take place.

The results of the AGM voting will be made available on the Company's website.

**- End -**

**For further information, please refer to [www.novacyt.com](http://www.novacyt.com) or contact:**

### **Contacts**

#### **Novacyt SA**

David Allmond, Chief Executive Officer  
James McCarthy, Chief Financial Officer  
+44 (0)1276 600081

#### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)  
+44 (0)20 3470 0470

#### **Numis Securities Limited (Joint Broker)**

Freddie Barnfield / James Black  
+44 (0)20 7260 1000

#### **Allegra Finance (French Listing Sponsor)**

Rémi Durgetto / Yannick Petit  
+33 (1) 42 22 10 10  
[r.durgetto@allegrafinance.com](mailto:r.durgetto@allegrafinance.com) / [y.petit@allegrafinance.com](mailto:y.petit@allegrafinance.com)

#### **FTI Consulting (International)**

Victoria Foster Mitchell / Alex Shaw  
+44 (0)20 3727 1000  
[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [Alex.Shaw@fticonsulting.com](mailto:Alex.Shaw@fticonsulting.com) /  
[Novacyt.group@fticonsulting.com](mailto:Novacyt.group@fticonsulting.com)

#### **FTI Consulting (France)**

Arnaud de Cheffontaines  
+33 (0)147 03 69 48

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

**About Novacyt Group**

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)